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Abstract
Background: The aim of this retrospective study was to report the prevalence and patterns of
soft tissue (ST) metastasis detected with true whole-body (TWB) F-18 FDG PET/CT acquired from
the top of the skull through the bottom of the feet and to compare such findings to that of the
typically acquired skull-base to upper-thigh, thus limited whole-body (LWB) field of view (FOV).
Methods:  TWB FDG-PET/CT scans were performed in 500 consecutive cancer patients.
Suspected ST metastasis was verified by correlation with surgical pathology, other imaging
modalities, or clinical follow-up.
Results: Nine out of 500 patients (1.8 %) had ST metastasis with a prevalence of 4/41 (9.8%) for
melanoma, 2/60 (3.3%) for lung carcinoma, 2/88 (2.3%) for lymphoma and 1/13 (77%) for
esophageal cancer. Those nine patients had a total of 41 ST lesions: 22 lesions within and 19 outside
of LWB FOV. Of those 41 lesions, 19 (46%) were subcutaneous and 22 (54%) were muscular
lesions. The presence of ST metastasis neither changed the staging nor the treatment in any of
these patients. However, the ST lesions provided a biopsy site in 4 of the 9 patients (44%). Seven
out of nine studied patients died of their disease within 1–22 months after ST metastasis was
diagnosed.
Conclusion: The detection of ST metastasis may have prognostic implications, provide more
accessible biopsy sites and help avoid invasive procedures. A LWB scanning may underestimate the
true extent of ST metastasis since a significant percentage of ST metastasis (46%) occurred outside
the typical LWB FOV.
Background
Distant metastasis to ST, defined as metastasis to skeletal
muscle and subcutaneous tissues, are rarely reported in
the literature. Autopsy series have reported ST metastasis
in 0.75%-9% of patients who died of metastatic carci-
noma [1-3]. The detection of ST metastasis may affect
staging and prognosis. Accurate tumor staging encom-
passing the entire body is important. There is a growing
body of literature regarding the added value of F-18 FDG
PET/CT in cancer patient management [4]. In oncology,
whole body PET/CT is typically performed from the skull
base to the pelvic floor [5,6] because most FDG avid
lesions are expected within this field of view. This FOV
correlates with that of diagnostic CT scans when separate
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scans of the neck, chest, abdomen and pelvis are per-
formed. If the primary tumor or the suspected metastatic
site is outside the LWB, the FOV is then extended to cover
this site, thus, allowing proper diagnosis, staging and
restaging. The LWB FOV may underestimate the true
extent of ST metastasis by missing lesions outside this
FOV. To our knowledge, there have been no studies sys-
tematically evaluating ST metastasis by F-18 FDG PET/CT.
The aim of this study was to report the prevalence and pat-
terns of ST metastasis detected with True Whole-Body
(TWB) F-18 FDG PET/CT, from the top of the skull
through the bottom of the feet, and to compare such find-
ings to that of the LWB FOV. Further, the implications of
ST metastasis on prognosis and patient management were
evaluated.
Methods
Patients
A total of 500 consecutive patients referred for clinical
evaluation of known malignancy and who had undergone
a PET/CT scan between September 2004 and February
2005 were retrospectively evaluated.
Inclusion and exclusion criteria
Criteria for inclusion were the presence of pathologically
proven malignancy and the development of metastatic ST
lesions in the skeletal muscles and/or subcutaneous tis-
sues confirmed by histopathology, clinical diagnosis or
other confirmatory imaging modalities. Lymph nodes,
lesions from direct tumor extension or along needle tracts
and suture lines were excluded. Tumor histology, location
and size of the primary lesion in patients with ST metasta-
sis were categorized.
PET/CT scanning
Patients fasted at least 4 hours before the tracer injection
and received an intravenous injection of approximately
5.18 MBq/Kg (0.14 mCi/Kg) of 18F-FDG, with a maxi-
mum of 444 MBq (12 mCi). Blood glucose level was
measured immediately prior to FDG injection and was <
200 mg in all studied cases. Patients were instructed to sit
in a quiet injection room without talking during the sub-
sequent 45–60 min of the FDG uptake phase and were
allowed to breathe normally during image acquisition
without specific instructions. All scans were acquired
using a PET/CT scanner (Gemini; Philips Medical Sys-
tems), with an axial co-scan range of 193 cm enabling a
head-to-toe (TWB) imaging in one sweep.
CT scanning
The CT scan of the PET/CT scanner consisted of a 16 slice
multi-detector helical CT. Gantry allows for a patient port
of 70 cm. Parameters were as follows for 12–13 bed acqui-
sitions (from the top of the head through the bottom of
the feet): 120–140 KV and 33–100 mAs (based on body
mass index), 0.5 second per CT rotation, pitch of 0.9 and
512 × 512 matrix. CT acquisition was performed before
emission acquisition. CT data were used for image fusion
and the generation of the CT transmission map. In all
patients, the arms were placed above the patient's head for
CT acquisition except in patients with head and neck can-
cers where the arms were placed at the patient's sides. No
oral or IV contrast was used. No separate CT interpretation
was performed since the CT was of suboptimal quality.
PET scanning and image processing
Emission data were acquired for 12–13 bed positions
(193 cm coverage, identical to CT protocol). Emission
scans were acquired at 3 minutes per bed position. The
FOV was TWB on all patients. The 3D TWB acquisition
parameters consisted of a 128 × 128 matrix and 18 cm
FOV with a 50% overlap. Processing consisted of the 3D
Row Action Maximum Likelihood Algorithm (RAMLA)
method [7].
Image analysis
TWB PET/CT images were retrospectively evaluated on
Syntegra workstation (Philips Medical Systems), by two
board certified Nuclear Medicine physicians, and a log
was kept to record whether cases with the suspected
lesions occurred within or outside the typical LWB FOV
(base of skull to upper-thigh or pelvic floor). The distribu-
tion of ST lesions was evaluated as inside or outside LWB
field of view, and the lesions were grouped as in the head,
upper or lower extremities. All ST lesions were evaluated
semi-quantitatively using maximum standard uptake val-
ues (SUVmax); SUVmax of the ST lesions and of the liver,
as reference organ, were compared. A standardized spher-
ical region of interest of 20 cm3 was placed in the mid lat-
eral aspect of the right hepatic lobe. Computer
tomographic evaluation of the ST lesions included meas-
urement of the largest diameter and a density judgment
(iso-, hyper- or hypodense compared to the surrounding
tissues). Given the limited anatomical delimitation of iso-
dense muscular lesions from the surrounding normal
muscular tissue on CT, the size of these lesions was esti-
mated on the PET study. A board-certified Oncologist
assessed the impact on management and/or staging from
the detection of malignancy outside the LWB FOV.
For statistical analysis, a Student t-test was used to com-
pare the results from subcutaneous and skeletal muscle
lesions. This retrospective study was approved by the
Institutional Review Board and patients' informed con-
sent was waived.
Results
The TWB PET/CT studies suggested the presence of ST
metastasis in 11 out of 500 studied patients (2.2%). False
positive findings were present in 2 of 11 patients whichBMC Medical Imaging 2007, 7:8 http://www.biomedcentral.com/1471-2342/7/8
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included one biopsy-proven actinic keratosis and one
axillary skin folding which initially was misinterpreted as
suspicious for skin metastasis; clinical exam of the axilla
was unremarkable, and the patient has remained in com-
plete remission by clinical exam and follow-up PET/CT.
ST metastasis was confirmed in the remaining 9 patients
(3 females, 6 males, age range 35–76, mean age 60).
Those 9 patients had a total of 41 ST lesions. Twenty two
lesions were within the LWB FOV (54%) and 19 lesions
outside it (46%). Three lesions were in the head, 14 in the
torso, 4 in the upper extremities and 20 in the lower
extremities. Subcutaneous lesions were 19 (46%) and
muscular lesions were 22 (54%). No ST metastasis was
found in the following patient populations: 32 breast can-
cers, 45 colorectal cancers, 29 cancers of the hepatobiliary
system, 50 head and neck cancers, 10 pancreatic cancers,
9 renal cell cancers, 10 cancers of the reproductive system,
12 sarcomas, 8 thyroid cancers and 91 miscellaneous can-
cers (unknown primary, non-specified cancer, cancer of
the bone, glioblastoma etc.). Melanoma was encountered
in 4 of the 9 cases (44%) and represented, with a preva-
lence of 4/41 (9.8%), the most frequent neoplasm with
metastasis outside the LWB FOV (Figure 1). Of the 4
patients with melanoma, two had ST metastasis in close
proximity to the primary lesion (scalp, thigh) which can
be classified as in-transit metastasis. The remaining 2
patients had the primary lesion in left upper arm and right
anterior chest. All melanoma patients presented with
simultaneous widespread ST metastasis and other distant
metastasis within and outside LWB. Lymphoma and lung
carcinoma represented with 2 cases each and corre-
sponded to a prevalence of 2/60 (3.3%) and 2/88 (2.3%),
respectively. Although represented with only one case,
esophageal cancer had a prevalence of 1/13 (7.7%) repre-
senting a higher prevalence when compared to lymphoma
or lung carcinoma given the relatively small number of
patients with esophageal cancer.
The distribution and clinical features of ST metastasis in
the 9 patients are shown in Table 1.
Seven out of the 9 patients developed ST metastasis within
12 months of diagnosis of the primary malignancy. The
remaining two patients had melanoma and developed ST
metastasis 4 years after the initial diagnosis. These later
patients died within 5 months and 8 months, respectively,
after the diagnosis of ST metastasis.
All 9 patients presented with other metastasis by the time
ST metastasis was identified (see Figures 1 and 2). The
71-year-old male with history of melanoma in the right anterior chest, status post surgical resection and interleukin-2 therapy  2 weeks prior to the PET/CT scan Figure 1
71-year-old male with history of melanoma in the right anterior chest, status post surgical resection and interleukin-2 therapy 
2 weeks prior to the PET/CT scan. Maximum intensity projection (MIP) image (A) and transaxial images (B, C and D) show 
widespread metastatic disease including three ST lesions in the left scalp (arrow), left mid back (arrow head) and left distal 
thigh (pentagon).
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Table 1: Distribution and clinical features of soft tissue metastasis of 9 included patients
Patient 
no.
Gender; 
age (y)
Cancer type; initial 
staging
Location, size/grading 
of primary lesion
Inside LWB – Sq Outside LWB – Sq Inside LWB – Sm Outside LWB – Sm Months from 
initial Dx to Dx 
of STM
Months of 
survival
Type of 
follow-up
1 M; 35 Melanoma; III Left scalp, 4.3 mm† 1: lt post-auricular* 0 0 0 3 DOD, 25 B
2 M; 71 Melanoma; III Left upper arm, size n/a 10: lt shoulder, 
abdomen, back, pelvis, 
lt thigh
2: lt elbow, lt thigh 2: rt shoulder, rt thigh 7: rt thigh, lt thigh, lt 
lower leg
48 DOD, 56 B
3 M; 70 Melanoma, spindle type; IV Right anterior chest, 1.4 
mm†
1: lt face 1: lt parietal skin 0 0 48 DOD, 53 B
4 M; 76 Melanoma; III Right thigh, 4.8 mm† 0 1: rt thigh* 0 0 4 DOD, 7 B
5 F; 65 Lung cancer, squamous ; IV Left lung, 5.5 cm 0 0 1: rt paraspinal 0 6 DOD, 7 C
6 M; 44 Lung cancer, non-small cell 
with squamoid features; IV
Left lung, 3.8 cm 0 1: lt thigh 2: rt shoulder, lt thigh 0 1 DOD, 9 C
7 F; 64 Lymphoma, follicular cell; IV Widespread tumor, grade 
II/III
1: rt chest 0 0 0 1 NED, 29 P
8 F; 56 Lymphoma, diffuse large B-
cell, anaplastic variant; II
Left groin 5.1 cm; 
retroperitoneum, 4.5 cm
0 1: rt elbow 1: rt thigh 3: rt thigh, lt thigh 7 n/a C
9 M; 63 Esophagealcancer, 
adenocarcinoma; staging n/a
Size n/a 0 0 3: lt arm, lt pelvis 3: lt thigh, rt calf, lt calf 12 DOD, 13 C
Total lesion number 13 6 9 13
SUVmax 5.5 ± 2.8 (1.5 – 9.6); all 
higher than liver uptake
8.9 ± 12.6 (1.0 – 37); 3/
6 higher than liver 
uptake
5.8 ± 3.0 (2.2 – 10); all 
higher than liver 
uptake
3.4 ± 2.5 (0.9 – 8.4); 11/
13 higher than liver 
uptake
CT appearance 13/13 hyperdense 6/6 hyperdense 4/9 isodense, 5/9 
hypodense
8/13 isodense, 5/13 
hypodense
Lesion size 8/13, < 1.5 cm; 5/13, 
1.5 – 1.8 cm
4/6, < 1.5 cm; 2/6, 1.5 – 
1.8 cm
1/9, < 1.5 cm; 8/9, 2.5 
– 2.8 cm
7/13, < 1.5 cm; 6/13, 1.5 
– 9 cm
LWB, limited whole body; Sq, subcutaneous; Sm, skeletal muscle; rt, right; lt, left; NSCLC, non-small cell lung cancer; DOD, death of disease; NED, no evidence of disease; n/a, not available; STM, soft tissue metastasis; B, biopsy; C, clinical; P, 
PET/CT
* in-transit metastasis; † Breslow's depthBMC Medical Imaging 2007, 7:8 http://www.biomedcentral.com/1471-2342/7/8
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presence of ST metastasis therefore neither changed the
staging nor treatment decisions in any of these patients.
However, the ST lesions provided a more accessible
biopsy site in 4 of the 9 patients (44%). Seven out of 9
patients died of their disease. The mean duration from ini-
tial diagnosis of the disease to death was 24 months
(range 7–56 months); while the mean duration from ST
metastasis diagnosis to death was 7 months (range 1–22
months). The remaining 2 patients were the two lym-
phoma patients: one had no evidence of residual disease;
and clinical data were not available for the other.
All ST metastatic lesions were FDG avid; 37/41 (90%)
lesions presented with SUVmax higher than in the liver,
thus, allowing easy identification of the lesions on the PET
study. The remaining 4/41 (10%) had slightly less FDG
uptake than in the liver and were < 1.5 cm in size; how-
ever, these lesions were identifiable as they were sur-
rounded by normal soft tissue that did not have any
significant FDG uptake. SUVmax was not statistically sig-
nificant (p = 0.394) between subcutaneous lesions (mean
5.2 +/- 3.8) and skeletal muscle lesions (mean 4.3 +/- 2.9).
The size of the ST metastatic lesions ranged from < 1 cm
to 9 cm with 20/41 (49%) being less than 1.5 cm and the
remaining 51% being between 1.5 – 9 cm. The sizes of
subcutaneous lesions (mean 1.2 +/- 0.3), and skeletal
muscle lesions (mean 2.2 +/- 2.2), did not differ signifi-
cantly (p = 0.106); but skeletal muscle lesions tended to
be larger than the subcutaneous ones. Subcutaneous
lesions were easily identifiable as hyperdense lesions on
CT. Skeletal muscle lesions were hypodense in 10/22
(45%) and isodense in 12/22 (55%). No hyperdense skel-
etal muscle lesions were noted.
Discussion
Our study showed that 9 of 500 (1.8%) cancer patients
had ST metastasis. Spencer et al. reported the prevalence
of skin metastasis of any cancer type to vary between
0.75% and 9% [1]. Other studies in lung cancer patients
revealed a lower and less variable cutaneous metastasis
prevalence of 1.3% to 3.1% which is comparable to our
findings [2,3]. The most commonly reported primary car-
cinomas to result in clinically recognized ST metastasis are
those of the lung, kidney, and colon [8]. Our study indi-
cated that the prevalence of ST metastasis of lung carci-
noma (2.3%) was much lower as compared to that of
melanoma (9.8%) which is higher than is reported in the
literature [8]. Our study showed that either in-transit or
distant ST metastasis was associated with other distant
metastasis, and was suggestive of poor prognosis as dem-
onstrated previously [9,10]. Of note, three of the four
melanoma patients were older than 70 years. This obser-
44-year-old male with history of non-small cell lung carcinoma Figure 2
44-year-old male with history of non-small cell lung carcinoma. MIP image (A) and transaxial images (B, C and D) show the pri-
mary lesion in the left lung (dotted arrow), a single subcutaneous ST lesion in the left proximal thigh (pentagon) and a bone 
lesion in the right distal tibia (arrow head).
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vation might have prognostic significance as older indi-
viduals with melanoma have increased mortality as
compared with younger ones [11]. However, this requires
future evaluation in a larger cohort of melanoma patients.
Two of 3 patients with available Breslow's depth showed
lesion thickness greater than 4 mm (pT4) which is indica-
tive of high risk neoplasms and may explain the wide-
spread disease in these patients. Lymphoma has rarely
been reported to have ST metastasis [8]. However, we
found an equal number of cases with ST metastasis in the
lymphoma and lung carcinoma cohorts (2 cases each).
Among the lymphoma cases, one had a CD30 positive,
anaplastic variant, diffuse large B-cell lymphoma poten-
tially explaining the development of ST metastasis. The
other patient had a grade III follicular lymphoma with a
single subcutaneous lesion and limited lymphadenopa-
thy. Additional research is needed to fully comprehend
the prevalence and pattern of ST metastasis in lymphoma.
The most frequently reported locations for ST metastasis
have been the back, chest wall, and abdomen [12]. These
are the areas typically included in chest, abdomen and
pelvis CT scans as well as the LWB PET/CT scans. In con-
trast, our study showed that ST metastasis occurred out-
side the typical LWB FOV in 46% of cases (19/41 lesions).
Thus, previously reported prevalence and locations of ST
metastasis may have been biased by the imaged FOV. ST
metastasis has been reported as a common clinical presen-
tation of occult malignancy and as an isolated metastasis
in the patient with a known malignancy [8,13]. Only a
small percentage of ST metastasis has been reported to
occur in the presence of disseminated disease [8,14]. In
contrast, our findings revealed that all patients with ST
metastasis had widespread disease on PET/CT. Our study
also indicated that ST metastasis can occur early during
the course of the disease since 7 out of 9 patients devel-
oped ST metastasis within 12 months of diagnosis of their
primary malignancy. It is likely that patients with
advanced disease have been underrepresented in the liter-
ature as they neither present a diagnostic challenge nor
have a curative therapy. Moreover, previous studies
mostly revealed a referral bias as the reported patients had
symptomatic ST lesions referred for further evaluation
and management [8,11].
Although magnetic resonance imaging (MRI) is not spe-
cific for soft tissue metastasis, it has been advocated as an
indispensable tool for the diagnosis and treatment plan-
ning in patients with soft tissue malignancy [15]. How-
ever, a recent study showed that F-18 FDG PET/CT has
higher sensitivity than MRI in detecting skin and ST
metastasis [16]. This is supportive of the increasing role of
F-18 FDG PET/CT in cancer patient management [4]. Nev-
ertheless, there are undoubtedly false positives as seen in
two cases (actinic keratosis, skin folding) of the studied
population that need to be taken into account. FDG
uptake and resulting increased tracer activity is not limited
to neoplastic tissue. Recognizing the strengths and weak-
nesses of PET is important for the accurate interpretation
of the PET/CT images. The diagnosis of ST metastasis in
our study using combined PET/CT was relatively straight-
forward as most lesions had significant FDG uptake
higher than that of the liver which is a widely accepted ref-
erence organ to distinguish benign from malignant
lesions. Most PET facilities recommend at least 4 hours of
fasting before the tracer injection as a standard. A longer
fasting time may increase the detection of ST lesions; how-
ever, the standard protocol of at least 4 hours fasting was
followed in this retrospective study. PET/CT protocol in
cancer staging usually comprises a low dose, non-
enhanced CT protocol [17,18], which is sufficient for
attenuation correction and anatomical information while
keeping the radiation exposure to a minimum. Given the
low-dose and non-contrast enhanced protocol, the CT
portion of the study helped localize the lesions and
increase the diagnostic confidence as ST metastatic lesions
can appear hyperdense or hypodense as compared to the
surrounding soft tissue.
ST metastasis can be present in many muscular and sub-
cutaneous sites across the body with a ratio higher than
1.5:1 [8]. In our study, the ratio was 1.2:1, suggesting that
subcutaneous ST metastasis may have been under-
reported in the literature. One explanation for this may be
that subcutaneous lesions tended to be smaller than mus-
cular ones, although our findings did not reveal a statisti-
cally significant difference in these lesions' size (p =
0.106). Another potential reason is that 5/19 (26%) of the
subcutaneous lesions in our study were 1 cm or less in size
which may represent a diagnostic limitation for diagnostic
CT and MRI scans.
Certainly, the prognosis in the presence of ST metastasis
should be considered when weighing the merits of the
findings. Seven out of nine studied patients died of their
disease within 1–22 months after ST metastasis was diag-
nosed. This correlates with the reported median survival
ranging from less than 5 months to no greater than 19
months after the diagnosis of ST metastasis [8].
We acknowledge the limitations of our retrospective
study. We also realize that at many institutions, a TWB
imaging is frequently performed in melanoma patients
and probably would have detected the in-transit metasta-
sis in two of the four melanoma patients (scalp, thigh).
We intended to evaluate a cohort of 500 consecutive can-
cer patients with TWB PET/CT imaging and tried to delin-
eate the extent of ST metastasis in this population. PET/CT
is a relatively new technology that has already been shown
to benefit the management of a number of cancersBMC Medical Imaging 2007, 7:8 http://www.biomedcentral.com/1471-2342/7/8
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[18,19]. A recent literature-based evidence review
reported an average of 15% improvement in staging and
restaging accuracies of PET/CT over PET or CT alone in dif-
ferent cancers [4]. The superior ability of F-18 FDG-PET/
CT in the detection of metastatic disease can help provide
an easily accessible biopsy site and avoid unnecessary
invasive diagnostic procedures as it was the case in 4 of
our 9 patients (44%). This can result in less invasive pro-
cedures performed, decreasing morbidity and cost.
LWB PET/CT scanning is typically performed from the
skull base to the pelvic floor [5,6] because most FDG avid
lesions are expected to be within this field of view except-
ing cerebral metastasis which can be found in at least 20%
of cancer patients during their life-time [20]. However, the
sensitivity of F-18 FDG PET is suboptimal in detecting
brain metastases due to the intense physiologic back-
ground uptake in the brain and the hypometabolic nature
of some brain metastases [21]. Because of the higher sen-
sitivity and specificity of contrast-enhanced MRI for cere-
bral metastasis [21], the use of F-18 FDG PET/CT to
diagnose brain metastasis has become less desirable.
Despite multiple reports in the literature, the prevalence
of distant metastasis to the extremities is rare
[1,2,4,8,12,22,23]. This is most likely why the extremities
are usually not included in the field of view unless there is
a clinical suspicion for cancer in the extremities. In our
study, LWB scanning would have under-diagnosed all
lesions outside LWB FOV. We found that 19/41 (46%) of
ST metastatic lesions were detected outside the LWB FOV,
i.e. could only be detected by TWB scanning.
A decision whether a TWB scanning should be used in
cancer patients depends on the overall prevalence of dis-
tant metastasis outside the LWB FOV which is not limited
to ST metastasis alone. The added value of TWB scan over
LWB scan is beyond the scope of this manuscript. How-
ever, analyzing the same patient cohort of the current
study, we found that distant metastasis occurred outside
of LWB FOV in 28/500 (5.6%) patients [24]. The detec-
tion of such lesions had direct patient management in
about 50% of the patients because of upstaging (unpub-
lished data). The tumors with the highest prevalence (>
10%) of distant metastasis outside the LWB were
melanoma and lung cancer. Therefore, TWB imaging for
malignant melanoma and lung cancer would be a reason-
able option and most beneficial for these two malignan-
cies. However, metastasis outside of LWB in other cancers
has the potential pitfall of a low overall prevalence of dis-
tant metastasis outside the LWB FOV. Of note, TWB imag-
ing requires additional several minutes of image
acquisition which can be uncomfortable for the patients
and results in decreased scanning throughput; however,
the time required for TWB image acquisition will continue
to decrease with advancements in both hardware and soft-
ware technology in newer PET/CT scanner designs that
would allow increased scanning throughput without
compromising imaging accuracy in an economical sense.
For example, the recently installed PET/CT scanner at our
institution is capable of acquiring a TWB scan in a patient
with a normal body mass index in less than 18 minutes.
Conclusion
The detection of ST metastasis may have prognostic impli-
cations, provide more accessible biopsy sites and help
avoid invasive procedures. A LWB scanning may underes-
timate the true extent of ST metastasis since a significant
percentage of ST metastasis (46%) occurred outside the
typical LWB FOV.
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